HAE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HAE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Haemonetics's enterprise value is USD4,526 Mil. Haemonetics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was USD1,270 Mil. Therefore, Haemonetics's EV-to-Revenue for today is 3.56.
The historical rank and industry rank for Haemonetics's EV-to-Revenue or its related term are showing as below:
During the past 13 years, the highest EV-to-Revenue of Haemonetics was 8.23. The lowest was 1.78. And the median was 3.77.
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
As of today (2024-03-19), Haemonetics's stock price is USD75.79. Haemonetics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was USD24.73. Therefore, Haemonetics's PS Ratio for today is 3.06.
The historical data trend for Haemonetics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Haemonetics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Haemonetics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Haemonetics's EV-to-Revenue falls into.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
Haemonetics's EV-to-Revenue for today is calculated as:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 4525.687 | / | 1270.181 | |
= | 3.56 |
Haemonetics's current Enterprise Value is USD4,526 Mil.
Haemonetics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was USD1,270 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haemonetics (NYSE:HAE) EV-to-Revenue Explanation
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
Haemonetics's PS Ratiofor today is calculated as:
PS Ratio | = | Share Price (Today) | / | Revenue per Share (TTM) |
= | 75.79 | / | 24.734 | |
= | 3.06 |
Haemonetics's share price for today is USD75.79.
Haemonetics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was USD24.73.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Haemonetics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Stewart W Strong | officer: President, Global Hospital | C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110 |
Anila Lingamneni | officer: EVP, Chief Technology Officer | HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110 |
Charles J Dockendorff | director | COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048 |
Diane M Bryant | director | 2200 MISSION COLLEGE BLVD, SANTA CLARA CA 95054 |
Josep Llorens | officer: EVP, Global Manufacturing | HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184 |
Michelle L Basil | officer: EVP and General Counsel | HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184 |
Farris Maryanne Maunsell | officer: VP, Chief Accounting Officer | C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110 |
Roy Galvin | officer: President, Global Plasma & BC | C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110 |
Laurie A. Miller | officer: SVP, Human Resources | C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110 |
Mark W Kroll | director | PO BOX 23, CRYSTAL BAY MN 55323 |
Dan Goldstein | officer: VP, Corporate Controller | HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184 |
Christopher Simon, | director, officer: President & CEO | HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184 |
James Darecca | officer: EVP, Chief Financial Officer | C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110 |
Burke William P. Mr. | officer: EVP, Chief Financial Officer | HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184 |
Lloyd Emerson Johnson | director | 16737 NEW PROVIDENCE LANE, CHARLOTTE NC 28277 |
From GuruFocus
By PRNewswire 01-06-2023
By PRNewswire 08-10-2022
By PRNewswire 03-02-2023
By PRNewswire 05-11-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.